CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference BASEL, Switzerland and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...

CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing - Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 (GLOBE...

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative...

CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference BASEL, Switzerland and CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology...